Sigma receptors: biology and therapeutic potential

被引:208
作者
Guitart, X [1 ]
Codony, X [1 ]
Monroy, X [1 ]
机构
[1] Esteve SA, Biol Discovery & CNS Res Dept, Res Ctr, Barcelona 08041, Spain
关键词
sigma receptors; schizophrenia; drug abuse; clinical potential; brain disorder;
D O I
10.1007/s00213-004-1920-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
More than 20 years after the identification of the sigma receptors as a unique binding site in the brain and in the peripheral organs, several questions regarding this receptor are still open. Only one of the subtypes of the receptor has been cloned to date, but the endogenous ligand still remains unknown, and the possible association of the receptor with a conventional second messenger system is controversial. From the very beginning, the sigma receptors were associated with various central nervous system disorders such as schizophrenia or movement disorders. Today, after hundreds of papers dealing with the importance of sigma receptors in brain function, it is widely accepted that sigma receptors represent a new and different avenue in the possible pharmacological treatment of several brain-related disorders. In this review, what is known about the biology of the sigma receptor regarding its putative structure and its distribution in the central nervous system is summarized first. The role of sigma receptors regulating cellular functions and other neurotransmitter systems is also addressed, as well as a short overview of the possible endogenous ligands. Finally, although no specific sigma ligand has reached the market, different pharmacological approaches to the alleviation and treatment of several central nervous system disorders and deficits, including schizophrenia, pain, memory deficits, etc., are discussed, with an overview of different compounds and their potential therapeutic use.
引用
收藏
页码:301 / 319
页数:19
相关论文
共 224 条
[1]   Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant [J].
Akunne, HC ;
Zoski, KT ;
Whetzel, SZ ;
Cordon, JJ ;
Brandon, RM ;
Roman, F ;
Pugsley, TA .
NEUROPHARMACOLOGY, 2001, 41 (01) :138-149
[2]   Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system [J].
Alonso, G ;
Phan, VL ;
Guillemain, I ;
Saunier, M ;
Legrand, A ;
Anoal, M ;
Maurice, T .
NEUROSCIENCE, 2000, 97 (01) :155-170
[3]   Neuropeptide Y mediated enhancement of NMDA-stimulated [3H]dopamine release from rat prefrontal cortex is reversed by σ1 receptor antagonists [J].
Ault, DT ;
Werling, LL .
SCHIZOPHRENIA RESEARCH, 1998, 31 (01) :27-36
[4]   Differential modulation of NMDA-stimulated [H-3]dopamine release from rat striatum by neuropeptide Y and sigma receptor ligands [J].
Ault, DT ;
Werling, LL .
BRAIN RESEARCH, 1997, 760 (1-2) :210-217
[5]   The sigma receptor as a ligand-regulated auxiliary potassium channel subunit [J].
Aydar, E ;
Palmer, CP ;
Klyachko, VA ;
Jackson, MB .
NEURON, 2002, 34 (03) :399-410
[6]  
Bartoszyk GD, 1996, CNS DRUG REV, V2, P175
[7]  
BASILE AS, 1992, MOL PHARMACOL, V42, P882
[8]   REGULATION OF SIGMA-RECEPTORS - HIGH-AFFINITY AND LOW-AFFINITY AGONIST STATES, GTP SHIFTS, AND UP-REGULATION BY RIMCAZOLE AND 1,3-DI(2-TOLYL)GUANIDINE [J].
BEART, PM ;
OSHEA, RD ;
MANALLACK, DT .
JOURNAL OF NEUROCHEMISTRY, 1989, 53 (03) :779-788
[9]   Effects of low and high doses of selective sigma ligands: Further evidence suggesting the existence of different subtypes of sigma receptors [J].
Bergeron, R ;
Debonnel, G .
PSYCHOPHARMACOLOGY, 1997, 129 (03) :215-224
[10]   Neuropeptide Y and the calcitonin gene-related peptide attenuate learning impairments induced by MK-801 via a sigma receptor-related mechanism [J].
Bouchard, P ;
Maurice, T ;
StPierre, S ;
Privat, A ;
Quirion, R .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1997, 9 (10) :2142-2151